학술논문
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT
Document Type
article
Author
Source
Mediterranean Journal of Hematology and Infectious Diseases, Vol 15, Iss 1 (2023)
Subject
Language
English
ISSN
2035-3006
Abstract
Introduction: Autologous stem cell transplantation (ASCT) following high-dose chemotherapy is applied for patients with relapsed/refractory (r/r) DLBCL. However, prognosis of relapsing DLBCL post-ASCT remained poor until the availability of CAR-T cell treatment. To appreciate this development, understanding the outcome of these patients in the pre-CAR-T era is essential. Methods: We retrospectively analyzed 125 consecutive DLBCL patients who underwent HDCT/ASCT. Results: After a median follow-up of 26 months, OS and PFS were 65% and 55%. 53 patients (42%) had a relapse (32 patients, 60%) or refractory disease (21 patients, 40%) after a median of 3 months post-ASCT. 81% of relapses occurred within the first year post-ASCT with an OS of 19% versus 40% at last follow-up in patients with later relapses (p=0.0022). Patients with r/r disease after ASCT had inferior OS compared to patients in ongoing remission (23% versus 96%; p